Literature DB >> 3021323

Restless legs syndrome and periodic movements in sleep: physiopathology and treatment with L-dopa.

J Montplaisir, R Godbout, G Poirier, M A Bédard.   

Abstract

Seven patients suffering from restless legs syndrome (RLS) and periodic movements in sleep (PMS) were investigated before and after treatment with L-Dopa. The effect of treatment was evaluated by polysomnography, structured interviews, and daily questionnaires. Sleep organization and subjective complaints improved during treatment with 100 to 200 mg of L-Dopa. Polysomnographic recordings also revealed a significant decrease of periodic leg movements during the first third of the night and a rebound during the last third. These results and previous biochemical findings raise the hypothesis that RLS and PMS may both result from reduced dopaminergic activity in the CNS, perhaps resulting from decreased sensibility of postsynaptic receptors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3021323     DOI: 10.1097/00002826-198610000-00006

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  16 in total

1.  Myoclonus.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-05       Impact factor: 3.598

2.  Restless legs syndrome and leg cramps in fibromyalgia syndrome: a controlled study.

Authors:  M B Yunus; J C Aldag
Journal:  BMJ       Date:  1996-05-25

3.  Restless legs syndrome/Willis-Ekbom disease prevalence in beta thalassemia patients.

Authors:  Euthimia Dimitriadou; Christoforos D Giannaki; Maria Tsekoura; Ioannis Stefanidis; Georgios M Hadjigeorgiou; Eleftherios Lavdas; Christina Karatzaferi; Giorgos K Sakkas
Journal:  Sleep Breath       Date:  2017-04-19       Impact factor: 2.816

4.  Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus L-Dopa.

Authors:  J Staedt; F Wassmuth; U Ziemann; G Hajak; E Rüther; G Stoppe
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 5.  Connectome and molecular pharmacological differences in the dopaminergic system in restless legs syndrome (RLS): plastic changes and neuroadaptations that may contribute to augmentation.

Authors:  Christopher J Earley; George R Uhl; Stefan Clemens; Sergi Ferré
Journal:  Sleep Med       Date:  2016-06-27       Impact factor: 3.492

6.  Misinterpretation of sleep-breathing disorder by periodic limb movement disorder.

Authors:  R A Stoohs; H C Blum; B Y Suh; C Guilleminault
Journal:  Sleep Breath       Date:  2001-09       Impact factor: 2.816

7.  Dopamine D2 receptor alteration in patients with periodic movements in sleep (nocturnal myoclonus).

Authors:  J Staedt; G Stoppe; A Kögler; D Munz; H Riemann; D Emrich; E Rüther
Journal:  J Neural Transm Gen Sect       Date:  1993

8.  Psychosomatic symptom profiles in patients with restless legs syndrome.

Authors:  Jung Bin Kim; Yong Seo Koo; Mi-Yeon Eun; Kun-Woo Park; Ki-Young Jung
Journal:  Sleep Breath       Date:  2013-01-23       Impact factor: 2.816

9.  Neurotoxic lesions at the ventral mesopontine junction change sleep time and muscle activity during sleep: an animal model of motor disorders in sleep.

Authors:  Y-Y Lai; K-C Hsieh; D Nguyen; J Peever; J M Siegel
Journal:  Neuroscience       Date:  2008-04-16       Impact factor: 3.590

Review 10.  Restless legs syndrome: pathophysiology, diagnosis and treatment.

Authors:  Pankaj Satija; William G Ondo
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.